Researchers have developed a two-step workflow using a new blood-based p-tau217 biomarker to improve the accuracy of Alzheimer’s Disease (AD) diagnosis. The first step uses a diagnostic model that combines plasma p-tau217 with age and the APOE e4 gene to identify high-risk patients.